Evaluation of the Pharmacokinetics and dosimetry of 225Ac Alpha Radionuclide Carriers

Abstract

Introduction: The use of 225Ac for alpha radionuclide therapy is a relatively novel approach, where the dense energy deposition of alpha radiation is used to treat cancer more effectively. 225Ac has, compared to conventional radionuclides, a long half-life of 10 days and a long decay chain, yielding 4 alpha particles, 2 beta particles and several gamma rays. This long decay chain presents new challenges. Daughter radionuclides that separate from the radionuclide carrier during radioactive decay can end up freely circulating …